SOURCE: Plandai Biotechnology, Inc.

Plandai Biotechnology, Inc.

December 28, 2015 09:00 ET

Plandai Biotechnology, Inc. Gives Annual Report of Progress and Provides Projections for 2016

LONDON, UNITED KINGDOM--(Marketwired - Dec 28, 2015) - Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), a producer of highly bioavailable Phytofare® Catechin Complex, today reviewed the results and current standings for 2015 and discussed plans for the future as they look to 2016.

Roger Baylis-Duffield, Chief Executive Officer for Plandaí, stated, "Earlier in 2015, the company commenced production and sale of its Phytofare® Catechin Complex, a green tea-derived extract that which been clinically proven to have ten times greater oral bioavailability over generic catechin extracts and proven topical anti-aging benefits in skin hydration, scaliness, and roughness. Production was compromised, however, when a freak hailstorm destroyed most of our final crop. During the dormant tea-harvesting period, the factory underwent a thorough overhaul and reopened in late September. By December the factory was processing eight tons of leaf per day and, commencing January 2016, production is scheduled to increase to ten tons a day. Assuming we maintain this level of production continues through at least the end of May, Plandaí expects to have over 2 tons per month of Phytofare catechin complex available to sell to customers.

"From a sales standpoint," Mr. Duffield continued, "we've been fortunate to garner interest in Phytofare® from multiple large companies in the nutraceutical industry and have been steadily shipping product to customers since May of this year. We have striven to manage our costs and, owing in part to the strong dollar against the South African Rand, we are favorably positioned with respect to operations. Combined with our sales forecasts, we aim to achieve profitability by May 2016.

"We are currently completing the processing and extraction protocols including product profiling to begin producing Phytofare® Citrus Bioflavonoid Complex in late June when the tea goes dormant. Third party studies have shown that a high-dose citrus complex is effective in treating cold and flu symptoms, soft tissue injuries and inflammation. Our Phytofare® Citrus Complex will be the first high-bioavailability product of its kind brought to market. Citrus processing will continue through September 2016 when the next tea crop will be available for harvest.

"We also previously announced that in March 2016 we will commence a clinical trial of our Ph2 product in the poultry production industry. The trial will use a combination of our catechin and citrus complexes entrapped in the Pheroid® to determine the effectiveness in preventing diseases in poultry." Mr. Duffield explained, "Poultry diseases, while costly to the farmers, also pose a huge risk to the public, necessitating the use of vaccines and other synthetic treatment protocols in most commercial farms. The poultry industry currently faces enormous challenges with huge losses from diseases, viruses, mortality and the health issues with the final meat or egg products. With more consumers demanding an "organic" solution that doesn't result in huge losses to the industry, we view the Phytofare® Ph2 product as a potential game changer in animal husbandry."

Mr. Duffield concluded, "We made significant progress in 2015, realizing our goal of entering full-scale production, and are excited by the prospects of the coming year. Achieving profitability and positive cash flow from operations is our number one short-term goal as we also introduce two new products, Ph2 and the Catechin Complex. We appreciate our many shareholders who have shown patience as we've provided a huge economic uplift to the local indigenous community and built a zero-carbon footprint industrial facility in the heart of South Africa."

About Plandaí Biotechnology, Inc.

Plandaí Biotechnology, Inc. and its subsidiaries develop highly phyto-available™ extracts. Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its proprietary Phytofare® extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at http://www.sec.gov.

Contact Information